Equities

JiangXi Tianxin Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

JiangXi Tianxin Pharmaceutical Co Ltd

Actions
Consumer Staples Food Producers
  • Price (CNY)27.21
  • Today's Change-0.270 / -0.98%
  • Shares traded554.60k
  • 1 Year change+2.06%
  • Beta0.8697
Data delayed at least 15 minutes, as of Feb 12 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

JiangXi Tianxin Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of monomeric vitamin products. The Company's business encompasses B vitamins, other vitamins, and fine chemicals. The Company's main products include vitamin B6, vitamin B1, biotin, folic acid, vitamin B5, vitamin D3, ascorbyl palmitate, vitamin E powder, vitamin A and other products. The Company's fine chemicals mainly include alpha-acetyl-gamma-butyrolactone (ABL), cholesterol, sodium methoxide, and L-alanine. The Company's products are mainly used in the fields of feed, medicine and food. The Company mainly conducts its businesses in domestic and overseas markets.

  • Revenue in CNY (TTM)2.23bn
  • Net income in CNY617.04m
  • Incorporated2004
  • Employees2.68k
  • Location
    JiangXi Tianxin Pharmaceutical Co LtdLe'anjiang Industrial Park, Leping CityJINGDEZHEN 333300ChinaCHN
  • Phone+86 7 986709288
  • Fax+86 7 986702388
  • Websitehttp://www.txpharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Yizhong Pharmaceutical Co Ltd247.05m22.96m11.22bn65.00479.777.68--45.430.11320.11321.227.070.1630.95562.263,800,801.001.515.441.585.6481.3992.999.3036.907.84--0.0032.30-51.83---95.68--10.96--
Zhejiang CONBA Pharmaceutical Co., Ltd.6.58bn687.99m11.49bn8.26k17.001.62--1.750.26650.26652.542.800.66172.574.70796,529.007.138.519.6512.7451.8858.6410.7714.121.38--0.053241.54-3.23-0.75945.21--1.57--
Cansino Biologics Inc971.83m-142.03m11.51bn1.11k--3.05--11.85-0.5455-0.54553.9221.370.12710.58611.38879,482.50-1.86-4.08-2.29-5.3878.8045.31-14.62-27.513.29--0.2242--137.01226.4374.45--31.38--
Mayinglong Pharmaceutical Group Co Ltd3.77bn571.60m11.85bn2.65k20.742.76--3.141.331.338.759.970.72116.2311.991,421,812.0011.3810.7713.8213.3546.7742.4015.7814.394.58--0.022637.3118.856.6219.147.9734.4718.98
Chengdu Easton Biopharmaceuticals Co Ltd1.33bn241.37m11.92bn1.52k49.184.16--8.971.371.377.5516.230.38091.835.89873,161.506.928.098.449.8271.9081.7218.1620.103.12--0.044430.3720.827.345.1517.014.24--
Jiangxi Tianxin Pharmaceutical Co Ltd2.23bn617.04m12.03bn2.68k19.402.51--5.401.421.425.1110.930.39732.439.65830,883.1011.0117.1011.8821.1643.0442.9927.7230.124.31--0.072124.4117.351.7536.85-2.2035.06--
Henan Lingrui Pharmaceutical Co., Ltd.3.78bn799.61m12.45bn2.44k15.573.83--3.291.411.416.675.730.7111.898.061,553,625.0015.0811.9025.5218.8979.2674.3621.2116.460.9053--0.137973.975.7210.1727.1919.6714.2924.57
Zhejiang Hisun Pharmaceutical Co., Ltd.9.84bn546.80m12.71bn7.99k22.191.49--1.290.47780.47788.617.100.6233.085.321,230,310.003.482.335.814.3246.6441.265.583.990.66465.330.280329.47-5.65-2.44745.2445.22-26.0333.24
Shenzhen Chipscreen Biosciences Co Ltd850.99m7.28m12.73bn1.06k1,746.507.69--14.960.01790.01792.094.060.24412.404.06802,822.700.20890.00360.24790.004285.4891.310.85570.01811.79-0.63190.48340.0025.6330.51-228.97--15.08--
Beijing Foyou Pharma Co Ltd3.42bn463.07m12.80bn3.64k27.033.39--3.740.98630.98637.287.870.7333.279.59938,316.509.9912.5312.8217.6465.1768.0113.6213.022.52--0.007733.163.177.28-0.018817.4435.29--
Data as of Feb 12 2026. Currency figures normalised to JiangXi Tianxin Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
Zheshang Fund Management Co., Ltd.as of 30 Jun 202534.70k0.01%
China Southern Asset Management Co., Ltd.as of 30 Jun 202529.17k0.01%
Hongde Fund Management Co., Ltd.as of 30 Jun 202512.40k0.00%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 202510.67k0.00%
Broad Fund Management Co. Ltd.as of 30 Jun 20253.30k0.00%
AVIC Fund Management Co. Ltd.as of 30 Jun 20252.60k0.00%
UBS SDIC Fund Management Co., Ltd.as of 30 Jun 20251.90k0.00%
Baoying Fund Management Co., Ltd.as of 30 Jun 20251.20k0.00%
China Universal Asset Management Co., Ltd.as of 30 Jun 2025644.000.00%
Lion Fund Management Co., Ltd.as of 30 Jun 2025572.000.00%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.